Abstract:The nano‐sized extracellular matrix is conjugated with doxorubicin using cis‐aconitic anhydride to prepare extracellular matrix‐drug conjugates, endowing them with acid‐sensitive drug release properties. These conjugates can be internalized into tumor cells via hyaluronic acid receptors and integrins, enhancing tumor site accumulation and antitumor efficacy while reducing organ toxicity of doxorubicin. The extracellular matrix (ECM) engages in regulatory interactions with cell surface receptors through its constituent proteins and polysaccharides. Therefore, nano‐sized extracellular matrix conjugated with doxorubicin (DOX) is utilized to produce extracellular matrix‐drug conjugates (ECM‐DOX) tailored for targeted delivery to cancer cells. The ECM‐DOX nanoparticles exhibit rod‐like morphology, boasting a commendable drug loading capacity of 4.58%, coupled with acid‐sensitive drug release characteristics. Notably, ECM‐DOX nanoparticles enhance the uptake by tumor cells and possess the ability to penetrate endothelial cells and infiltrate tumor multicellular spheroids. Mechanistic insights reveal that the internalization of ECM‐DOX nanoparticle is facilitated through clathrin‐mediated endocytosis and macropinocytosis, intricately involving hyaluronic acid receptors and integrins. Pharmacokinetic assessments unveil a prolonged blood half‐life of ECM‐DOX nanoparticles at 3.65 h, a substantial improvement over the 1.09 h observed for free DOX. A sustained accumulation effect of ECM‐DOX nanoparticles at tumor sites, with drug levels in tumor tissues surpassing those of free DOX by several‐fold. The profound therapeutic impact of ECM‐DOX nanoparticles is evident in their notable inhibition of tumor growth, extension of median survival time in animals, and significant reduction in DOX‐induced cardiotoxicity. The ECM platform emerges as a promising carrier for avant‐garde nanomedicines in the realm of cancer treatment.

Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Functionalized Nanoscale Micelles Improve Drug Delivery for Cancer Therapy in Vitro and in Vivo.

Tumor therapy utilizing dual-responsive nanoparticles: A multifaceted approach integrating calcium-overload and PTT/CDT/chemotherapy

Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer

Co-assembly of polymeric conjugates sensitizes neoadjuvant chemotherapy of Triple-Negative Breast Cancer with reduced systemic toxicity

Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells

Tumor Microenvironment-Mediated Construction and Deconstruction of Extracellular Drug-Delivery Depots.

Tumor-homing, Ph- and Ultrasound-Responsive Polypeptide-Doxorubicin Nanoconjugates Overcome Doxorubicin Resistance in Cancer Therapy

Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy

Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy

Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer

Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate

Gene Reprogramming Armed Macrophage Membrane-Camouflaged Nanoplatform Enhances Bionic Targeted Drug Delivery to Solid Tumor for Synergistic Therapy

Coordinating Bioorthogonal Reactions with Two Tumor-Microenvironment-responsive Nanovehicles for Spatiotemporally Controlled Prodrug Activation

Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and Apoptosis

Sequential Delivery of Cyclopeptide RA-V and Doxorubicin for Combination Therapy on Resistant Tumor and In Situ Monitoring of Cytochrome c Release

Targeted delivery and stimulus-responsive release of anticancer drugs for efficient chemotherapy

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Enzyme- and Ph-Sensitive Branched Polymer-Doxorubicin Conjugate-Based Nanoscale Drug Delivery System for Cancer Therapy